Technologies
Built by scientists with deep preclinical expertise, LIDE delivers both proven, gold-standard models and exclusive proprietary platforms. Whether you need standalone studies or an integrated pre-IND program, our scientific engagement team can design custom studies to match your R&D goals.
2300+ Patient Derived Xenograft (PDX) Models
LIDE’s industry leading PDX library offers our clients access to unique, patient-consented, highly characterized, low-passage tumors:
· 50 oncology indications covered
· 370+ naturally derived resistant models
· World’s largest biobank of pretreated models
· Variant rich: rare mutations and high-profile targets
Learn More ›
MiniPDX®: the 7 Day In Vivo 3D Organoid
Our proprietary MiniPDX and IO-FIVE tests provide fast and actionable in-vivo feedback for your go or no-go development decisions.
· Results in 7-10 days
· Supports wider range of drugs and dosing protocols than in-vitro methods
· More cost effective than traditional PDX
· 92% correlated with PDX results
Learn More ›
Cell Line Derived Xenograft (CDX) Models
CDX models are a well established and a widely used for early in-vivo screening. LIDE has a growing bank ready for client application.
· 120 models ready to use. 46 with SOC data.
· New models established at minimal client cost
· Cost effective and fast turnaround time
Learn More ›
Orthotopic Models
We offer orthotopic models built on PDX and CDX tissue, and across a wide spectrum of solid and liquid cancers.
· Wide spectrum of cancer types and hematological tumors
· Available from PDX or CDX cells
· Luciferase-labeled tumor cells for non-invasive monitoring
Learn More ›
Ex Vivo Models
CR cell lines provide a much better starting point than traditional commercially available cell lines in compound screens or efficacy studies. Many with matching PDX models
· Frozen PDXO Biobank – 225 models across 21 cancer types, readily available with consistent post-thaw performance
· CR cell-derived organoids for matched 2D/3D/PDX investigation
· Co-culture assays for immuno-oncology
Learn More ›
Immuno Oncology Platform
LIDE offers a comprehensive suite of immuno-oncology models and assays to accelerate the development of checkpoint inhibitors, bispecific antibodies, cell therapies, ADCs, oncolytic viruses, and other IO agents.
· Murine and humanized syngeneic models for proof-of-concepts
· Donor-selected classic PBMC humanized models
· Novel HuPBMC/cancer co-inoculation model
· Effector engineered T/NK, Car-T, ADC and oncolytic virus
Learn More ›
Advanced OMICs and Bioanalytics
LIDE’s in-house bioanalytics team offers seamless transition from lab studies to data analysis, offering multi-omics approach with standard genomic analysis paired with advanced transcriptomics and single molecule proteomics.
· WES | RNAseq
· Flow Cytometry | IMC (Imaging Mass Cytometry)
· IHC | IF | Single | Multiplex
· ELISA | Immunoassay
Learn More ›